• Eight new services introduced into the EBM with extrabudgetary reimbursement
• Coreline Soft advances an operational AI strategy for multi-center reading and quality management
The Federal Joint Committee (G-BA) has decided to incorporate lung cancer screening using low-dose computed tomography (LDCT) for high-risk individuals into Germany’s statutory healthcare system, effective April 1, 2026.
With this decision, lung cancer screening will, for the first time, be established as a structured national program within routine care.
Reimbursement for these services will initially be provided on an extrabudgetary basis, meaning outside the morbidity-based total remuneration system.
From April 2026, a total of eight new services will be added to the German Uniform Value Scale (EBM), assigned to Section 1.7.2, “Early Detection of Diseases in Adults.”
A key feature of the new regulation is that not only the imaging examination itself is reimbursed, but the entire screening process is defined as a structured operational workflow.
Each step of the process is explicitly reflected in the EBM, meaning that hospitals and practices can only bill for services if all organizational, qualitative, and professional requirements are fulfilled.
This marks a clear shift from an examination-centered model to a process- and operations-driven screening structure.
The program requires an independent second reading by a qualified specialist following the initial interpretation.
In complex cases, a multidisciplinary case conference may also be required.
This necessitates the establishment of collaborative, cross-institutional reading structures.
Results must be documented in structured reporting formats, including quantitative parameters such as the size, volume, and growth dynamics of pulmonary nodules.
In addition, regular follow-up, typically at 12-month intervals, is an integral part of the program.
This requires continuous comparison and longitudinal analysis of imaging data.
Implementation will take place under strict GDPR requirements.
At the same time, the program requires standardized and interoperable data structures to ensure consistent quality assurance at the national level.
Hospitals must therefore adopt IT systems capable of meeting high security standards while enabling seamless integration into broader healthcare networks.
Against this backdrop, demand is increasing for integrated operational platforms that go beyond standalone AI analysis and support functions such as multi-center collaboration, quality management, and structured documentation.
Coreline Soft is responding to the introduction of extrabudgetary reimbursement with a strengthened market strategy.
With solutions including AVIEW LCS, AVIEW LCS Plus, and the centralized management platform AVIEW HUB, the company offers a plug-in-based architecture that integrates seamlessly into existing PACS and RIS systems while supporting the operational requirements for reimbursable implementation.
Within Germany’s national lung cancer screening pilot project HANSE, Coreline Soft has already demonstrated its technological capabilities. Using a single CT scan, the system enables simultaneous analysis of lung cancer, cardiovascular disease, and emphysema. The solutions are currently deployed at leading institutions, including Charité, as well as hospitals in Heidelberg, Bonn, and Klinikum Chemnitz.
Coreline Soft will also present its solutions at the upcoming RÖKO 2026 conference, one of Germany’s key radiology meetings, where industry stakeholders and clinical experts gather to discuss the operational implementation of lung cancer screening programs.
The company plans to showcase how its AI-driven platform supports multi-center collaboration.
2026.04.09
Contact us
General inquiries
Business Department
Overseas Business Department
Customer Service Team
IR-related inquiries
List